Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Chromosomal rearrangements involving neurotrophic tyrosine kinase 1 (NTRK1) occur in a subset of non-small cell lung cancers (NSCLCs) and other solid tumor malignancies, leading to expression of an oncogenic TrkA fusion protein. Entrectinib (RXDX-101) is an orally available tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Farago, Anna F., Le, Long P., Zheng, Zongli, Muzikansky, Alona, Drilon, Alexander, Patel, Manish, Bauer, Todd M., Liu, Stephen V., Ou, Sai-Hong I., Jackman, David, Costa, Daniel B., Multani, Pratik S., Li, Gary G., Hornby, Zachary, Chow-Maneval, Edna, Luo, David, Lim, Jonathan E., Iafrate, Anthony J., Shaw, Alice T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643748/
https://www.ncbi.nlm.nih.gov/pubmed/26565381
http://dx.doi.org/10.1097/01.JTO.0000473485.38553.f0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643748/
https://www.ncbi.nlm.nih.gov/pubmed/26565381
http://dx.doi.org/10.1097/01.JTO.0000473485.38553.f0

Ejemplares similares